CR20190566A - Inhibidores de quinasay usos de los mismos - Google Patents

Inhibidores de quinasay usos de los mismos

Info

Publication number
CR20190566A
CR20190566A CR20190566A CR20190566A CR20190566A CR 20190566 A CR20190566 A CR 20190566A CR 20190566 A CR20190566 A CR 20190566A CR 20190566 A CR20190566 A CR 20190566A CR 20190566 A CR20190566 A CR 20190566A
Authority
CR
Costa Rica
Prior art keywords
kinase inhibitors
intermediates
compositions
compounds
processes
Prior art date
Application number
CR20190566A
Other languages
English (en)
Inventor
Colin Philip Leslie
Arun Thottumkara
Cinzia María Francini
Vicente Fidalgo Javier De
Jianwen A Feng
Brian Fox
Maksim Osipov
Christopher R H Hale
Cheng Hu
Elena Serra
Zachary K Sweeney
Anthony A Estrada
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CR20190566A publication Critical patent/CR20190566A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/04—Seven-membered rings having the hetero atoms in positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente descripcion se refiere generalmente a compuestos y composiciones, intermedios, precedimientos para su preparación, y su uso como inhibidores de quinasa.
CR20190566A 2017-05-17 2018-05-17 Inhibidores de quinasay usos de los mismos CR20190566A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762507698P 2017-05-17 2017-05-17
US201862664895P 2018-04-30 2018-04-30
PCT/US2018/033266 WO2018213632A1 (en) 2017-05-17 2018-05-17 Kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CR20190566A true CR20190566A (es) 2020-06-14

Family

ID=64274744

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190566A CR20190566A (es) 2017-05-17 2018-05-17 Inhibidores de quinasay usos de los mismos

Country Status (20)

Country Link
US (2) US11203600B2 (es)
EP (1) EP3624797A4 (es)
JP (2) JP7064512B2 (es)
KR (1) KR102638151B1 (es)
CN (1) CN110913858A (es)
AU (1) AU2018269743B2 (es)
BR (1) BR112019023918A2 (es)
CA (1) CA3063934A1 (es)
CL (1) CL2019003263A1 (es)
CO (1) CO2019012957A2 (es)
CR (1) CR20190566A (es)
DO (1) DOP2019000290A (es)
EC (1) ECSP19089214A (es)
IL (1) IL270648B2 (es)
MX (2) MX2019013645A (es)
PE (1) PE20200729A1 (es)
PH (1) PH12019550235A1 (es)
SG (1) SG10201913927VA (es)
TW (1) TWI794232B (es)
WO (1) WO2018213632A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3116729A1 (en) * 2018-10-19 2020-04-23 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
WO2021187605A1 (ja) * 2020-03-19 2021-09-23 田辺三菱製薬株式会社 含窒素複素環αシアノカルボニル化合物
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途
KR200493347Y1 (ko) 2020-07-06 2021-03-17 박혜진 휴대가 용이한 마스크
AU2022222458A1 (en) * 2021-02-19 2023-08-24 Kalvista Pharmaceuticals Limited Factor xiia inhibitors
US11897876B2 (en) 2021-11-11 2024-02-13 Genzyme Corporation Isoxazolidines as RIPK1 inhibitors and use thereof
WO2024025817A1 (en) * 2022-07-25 2024-02-01 Denali Therapeutics Inc. Solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5- dihydro-2h-pyrido[3,4-f][l,4]oxazepine-9-carbonitrile
WO2024044151A1 (en) * 2022-08-23 2024-02-29 Genzyme Corporation Methods for treating receptor-interacting protein kinase 1-mediated diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3861187B2 (ja) * 1996-08-02 2006-12-20 住友精化株式会社 チアゼピン誘導体の製造方法
SK3632003A3 (en) * 2000-09-27 2003-09-11 Ajinomoto Kk Benzodiazepine derivatives, pharmaceutical composition comprising same and their use
RU2456287C1 (ru) * 2011-05-20 2012-07-20 Николай Филиппович Савчук Стимуляторы секреции инкретиновых гормонов, способы их получения и применения
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
TWI637951B (zh) * 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
CN104059068B (zh) * 2013-03-20 2017-02-08 中国科学院上海药物研究所 β‑氨基羰基类化合物、其制备方法、药物组合物及其用途
AU2016215432B2 (en) * 2015-02-02 2020-07-30 Valo Early Discovery, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
UY36680A (es) * 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
PL3307739T3 (pl) * 2015-06-15 2021-05-31 Glaxosmithkline Intellectual Property Development Limited Regulatory nrf2

Also Published As

Publication number Publication date
US20200087319A1 (en) 2020-03-19
PH12019550235A1 (en) 2020-07-20
CA3063934A1 (en) 2018-11-22
DOP2019000290A (es) 2020-03-15
JP2021193116A (ja) 2021-12-23
EP3624797A1 (en) 2020-03-25
JP7064512B2 (ja) 2022-05-10
IL270648B1 (en) 2023-11-01
CN110913858A (zh) 2020-03-24
TWI794232B (zh) 2023-03-01
ECSP19089214A (es) 2020-05-29
AU2018269743B2 (en) 2024-01-11
US11203600B2 (en) 2021-12-21
MX2022010755A (es) 2022-09-23
BR112019023918A2 (pt) 2020-06-02
CO2019012957A2 (es) 2020-05-29
JP2020520924A (ja) 2020-07-16
EP3624797A4 (en) 2021-07-21
IL270648B2 (en) 2024-03-01
AU2018269743A1 (en) 2020-01-16
KR102638151B1 (ko) 2024-02-16
PE20200729A1 (es) 2020-07-23
JP7241825B2 (ja) 2023-03-17
KR20200006125A (ko) 2020-01-17
TW201900618A (zh) 2019-01-01
MX2019013645A (es) 2020-09-17
SG10201913927VA (en) 2020-03-30
WO2018213632A1 (en) 2018-11-22
IL270648A (es) 2020-01-30
US20220041620A1 (en) 2022-02-10
CL2019003263A1 (es) 2020-04-17

Similar Documents

Publication Publication Date Title
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
MX2022010755A (es) Inhibidores de quinasa y usos de los mismos.
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MX2019011496A (es) Composiciones de niraparib.
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
MX2016012829A (es) Inhibidores de biaril cinasa.
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
SG10201902326XA (en) Mk2 inhibitors and uses thereof
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
EP3795578A3 (en) Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
MX2018007219A (es) Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов